Disclosed is the use of a pegylated or unpegylated aptamer in the preparation of a medicament, wherein: the pegylated or unpegylated aptamer binds to C5 complement; and the medicament is formulated for sequential or substantially simultaneous administration with an anti-VEGF agent and/or anti-PDGF agent, for treating, stabilizing and/or preventing macular degeneration in a subject.